VWF and thrombotic thrombocytopenic purpura: In addition, an anti-VWF antibody, caplacizumab, has already demonstrated promising clinical results in the treatment of thrombotic thrombocytopenic purpura and may also prevent microangiopathy in diseases associated with increased eryptosis56.